Category:Hematology: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) |
No edit summary |
||
| Line 20: | Line 20: | ||
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology | | rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Alpha thalassemia | *[[Alpha thalassemia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 30: | Line 30: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Microangiopathic hemolytic anemia | *[[Microangiopathic hemolytic anemia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 39: | Line 39: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Myelophthisic anemia | *[[Myelophthisic anemia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 50: | Line 50: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | * | ||
* Glucose-6-phosphate dehydrogenase deficiency | *[[Glucose-6-phosphate dehydrogenase deficiency]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 63: | Line 63: | ||
** Papular (SP) | ** Papular (SP) | ||
** Infectious (SP) | ** Infectious (SP) | ||
** Purpura fulminans | **[[Purpura fulminans]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 76: | Line 76: | ||
** | ** | ||
** | ** | ||
* Thrombotic micropangiopathies (LP) | *[[Thrombotic micropangiopathies]] (LP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 86: | Line 86: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* opangiopathies (LP) | *[[opangiopathies]] (LP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 96: | Line 96: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Hemophilia (LP)(Muhammad)(Abdelrahman) | *[[Hemophilia]] (LP)(Muhammad)(Abdelrahman) | ||
** Hemophilia A | **[[Hemophilia A (patient information)|Hemophilia A]] | ||
** Hemophilia B | **[[Hemophilia B (patient information)|Hemophilia B]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 108: | Line 108: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Neutrophilia (SP) | *[[Neutrophilia]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 118: | Line 118: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Neutropenia (SP) | *[[Neutropenia]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 128: | Line 128: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Lymphocytosis (SP) | *[[Lymphocytosis]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 138: | Line 138: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Monocytosis (SP) | *[[Monocytosis]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 148: | Line 148: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Eosiniphilia (SP) | *[[Eosiniphilia]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 158: | Line 158: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Basophilia (SP) | *[[Basophilia]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 168: | Line 168: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Lymphadenopathy (SP) | *[[Lymphadenopathy]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 178: | Line 178: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Transfusion therapy (SP) | *[[Transfusion therapy resident survival guide|Transfusion therapy]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 188: | Line 188: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Transfusion reactions (SP) | *[[Transfusion reaction|Transfusion reactions]] (SP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| Line 198: | Line 198: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Myeloproliferative neoplasms (LP) | *[[Myeloproliferative neoplasms]] (LP) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Revision as of 16:11, 21 June 2020
List of Chapters Requiring Content
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
|---|---|---|---|---|---|---|---|
| Hematology | |||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
|||||||
In progress chapters
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
|---|---|---|---|---|---|---|---|
| Hematology | |||||||
Completed chapters
| Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
|---|---|---|---|---|---|---|---|
| Hematology | |||||||
Subcategories
This category has the following 6 subcategories, out of 6 total.
Pages in category "Hematology"
The following 200 pages are in this category, out of 4,403 total.
(previous page) (next page)2
- 22q11.2 deletion syndrome causes
- 22q11.2 deletion syndrome chest x ray
- 22q11.2 deletion syndrome CT
- 22q11.2 deletion syndrome echocardiography
- 22q11.2 deletion syndrome electrocardiogram
- 22q11.2 deletion syndrome epidemiology and demographics
- 22q11.2 deletion syndrome history and symptoms
- 22q11.2 deletion syndrome laboratory findings
- 22q11.2 deletion syndrome medical therapy
- 22q11.2 deletion syndrome MRI
- 22q11.2 deletion syndrome other diagnostic studies
- 22q11.2 deletion syndrome other imaging findings
- 22q11.2 deletion syndrome overview
- 22q11.2 deletion syndrome pathophysiology
- 22q11.2 deletion syndrome physical examination
- 22q11.2 deletion syndrome primary prevention
- 22q11.2 deletion syndrome risk factors
- 22q11.2 deletion syndrome screening
- 22q11.2 deletion syndrome secondary prevention
- 22q11.2 deletion syndrome surgery
A
- Abdominal mass
- Abdominal mass (patient information)
- Abdominal mass case study one
- Abdominal mass causes
- Abdominal mass cost-effectiveness of therapy
- Abdominal mass CT
- Abdominal mass differential diagnosis
- Abdominal mass epidemiology and demographics
- Abdominal mass future or investigational therapies
- Abdominal mass history and symptoms
- Abdominal mass laboratory findings
- Abdominal mass medical therapy
- Abdominal mass MRI
- Abdominal mass natural history, complications and prognosis
- Abdominal mass other diagnostic studies
- Abdominal mass other imaging findings
- Abdominal mass overview
- Abdominal mass pathophysiology
- Abdominal mass physical examination
- Abdominal mass primary prevention
- Abdominal mass risk factors
- Abdominal mass secondary prevention
- Abdominal mass surgery
- Abdominal mass ultrasound
- Abdominal mass x ray
- Abnormalities in erythrocyte morphology
- ABO incompatibility (patient information)
- Absolute neutrophil count
- Acanthocytosis
- Acanthocytosis (patient information)
- Acanthocytosis case study one
- Acanthocytosis causes
- Acanthocytosis cost-effectiveness of therapy
- Acanthocytosis CT
- Acanthocytosis differential diagnosis
- Acanthocytosis epidemiology and demographics
- Acanthocytosis future or investigational therapies
- Acanthocytosis history and symptoms
- Acanthocytosis laboratory findings
- Acanthocytosis medical therapy
- Acanthocytosis MRI
- Acanthocytosis natural history, complications and prognosis
- Acanthocytosis other diagnostic studies
- Acanthocytosis other imaging findings
- Acanthocytosis overview
- Acanthocytosis pathophysiology
- Acanthocytosis physical examination
- Acanthocytosis prevention
- Acanthocytosis risk factors
- Acanthocytosis surgery
- Acquired disorders of the bone marrow
- Acquired hemolytic anemia
- Acral dysostosis - dyserythropoiesis
- Acral necrosis
- Activated clotting time
- Activated protein C resistance
- ACUITY HORIZONS bleeding criteria
- Acute basophilic leukemia
- Acute chest syndrome
- Acute chest syndrome case study one
- Acute chest syndrome causes
- Acute chest syndrome chest x ray
- Acute chest syndrome cost-effectiveness of therapy
- Acute chest syndrome CT
- Acute chest syndrome differential diagnosis
- Acute chest syndrome echocardiography or ultrasound
- Acute chest syndrome electrocardiogram
- Acute chest syndrome epidemiology and demographics
- Acute chest syndrome future or investigational therapies
- Acute chest syndrome historical perspective
- Acute chest syndrome history and symptoms
- Acute chest syndrome laboratory findings
- Acute chest syndrome medical therapy
- Acute chest syndrome MRI
- Acute chest syndrome natural history, complications and prognosis
- Acute chest syndrome other diagnostic studies
- Acute chest syndrome other imaging findings
- Acute chest syndrome overview
- Acute chest syndrome pathophysiology
- Acute chest syndrome physical examination
- Acute chest syndrome prevention
- Acute chest syndrome risk factors
- Acute chest syndrome screening
- Acute chest syndrome surgery
- Acute eosinophilic leukemia
- Acute lymphoblastic leukemia
- Acute lymphoblastic leukemia case study one
- Acute lymphoblastic leukemia chest x ray
- Acute lymphoblastic leukemia classification
- Acute lymphoblastic leukemia cost-effectiveness of therapy
- Acute lymphoblastic leukemia CT
- Acute lymphoblastic leukemia diagnostic study of choice
- Acute lymphoblastic leukemia differential diagnosis
- Acute lymphoblastic leukemia echocardiography and ultrasound
- Acute lymphoblastic leukemia electrocardiogram
- Acute lymphoblastic leukemia epidemiology and demographics
- Acute lymphoblastic leukemia future or investigational therapies
- Acute lymphoblastic leukemia historical perspective
- Acute lymphoblastic leukemia history and symptoms
- Acute lymphoblastic leukemia laboratory findings
- Acute lymphoblastic leukemia medical therapy
- Acute lymphoblastic leukemia MRI
- Acute lymphoblastic leukemia natural history, complications and prognosis
- Acute lymphoblastic leukemia other diagnostic studies
- Acute lymphoblastic leukemia other imaging findings
- Acute lymphoblastic leukemia overview
- Acute lymphoblastic leukemia pathophysiology
- Acute lymphoblastic leukemia physical examination
- Acute lymphoblastic leukemia primary prevention
- Acute lymphoblastic leukemia risk factors
- Acute lymphoblastic leukemia screening
- Acute lymphoblastic leukemia secondary prevention
- Acute lymphoblastic leukemia x ray
- Acute Lymphocytic Leukemia
- Acute megakaryoblastic leukemia
- Acute megakaryoblastic leukemia case study one
- Acute megakaryoblastic leukemia classification
- Acute megakaryoblastic leukemia cost-effectiveness of therapy
- Acute megakaryoblastic leukemia differential diagnosis
- Acute megakaryoblastic leukemia epidemiology and demographics
- Acute megakaryoblastic leukemia future or investigational therapies
- Acute megakaryoblastic leukemia history and symptoms
- Acute megakaryoblastic leukemia laboratory findings
- Acute megakaryoblastic leukemia medical therapy
- Acute megakaryoblastic leukemia natural history, complications and prognosis
- Acute megakaryoblastic leukemia other diagnostic studies
- Acute megakaryoblastic leukemia overview
- Acute megakaryoblastic leukemia pathophysiology
- Acute megakaryoblastic leukemia physical examination
- Acute megakaryoblastic leukemia surgery
- Acute monocytic leukemia case study one
- Acute monocytic leukemia causes
- Acute monocytic leukemia classification
- Acute monocytic leukemia cost-effectiveness of therapy
- Acute monocytic leukemia criteria
- Acute monocytic leukemia differential diagnosis
- Acute monocytic leukemia epidemiology and demographics
- Acute monocytic leukemia future or investigational therapies
- Acute monocytic leukemia historical perspective
- Acute monocytic leukemia history and symptoms
- Acute monocytic leukemia laboratory findings
- Acute monocytic leukemia medical therapy
- Acute monocytic leukemia natural history, complications and prognosis
- Acute monocytic leukemia other diagnostic studies
- Acute monocytic leukemia overview
- Acute monocytic leukemia pathophysiology
- Acute monocytic leukemia physical examination
- Acute monocytic leukemia prevention
- Acute monocytic leukemia risk factors
- Acute monocytic leukemia screening
- Acute monocytic leukemia surgery
- Acute myeloblastic leukemia (patient information)
- Acute myeloblastic leukemia causes
- Acute myeloblastic leukemia chest x ray
- Acute myeloblastic leukemia classification
- Acute myeloblastic leukemia cost-effectiveness of therapy
- Acute myeloblastic leukemia CT
- Acute myeloblastic leukemia differential diagnosis
- Acute myeloblastic leukemia epidemiology and demographics
- Acute myeloblastic leukemia future or investigational therapies
- Acute myeloblastic leukemia historical perspective
- Acute myeloblastic leukemia history and symptoms
- Acute myeloblastic leukemia laboratory tests
- Acute myeloblastic leukemia medical therapy
- Acute myeloblastic leukemia MRI
- Acute myeloblastic leukemia natural history
- Acute myeloblastic leukemia other diagnostic studies
- Acute myeloblastic leukemia overview
- Acute myeloblastic leukemia pathophysiology
- Acute myeloblastic leukemia physical examination
- Acute myeloblastic leukemia primary prevention
- Acute myeloblastic leukemia risk factors
- Acute myeloblastic leukemia screening
- Acute myeloblastic leukemia secondary prevention
- Acute myeloblastic leukemia surgery
- Acute myeloblastic leukemia with maturation
- Acute Myelogenous Leukemia
- Acute myeloid leukemia
- Acute myeloid leukemia (patient information)